Actos (pioglitazone) may have helped thousands of Americans, but it has also been a source of concern, conflict, and consternation for many patients, particularly consumers who have taken Actos, Actoplus Met, Duetact, and other pioglitazone-based drugs for longer than one year.
The Food and Drug Administration (FDA) has issued clear warnings in recent years that have underscored the very real potential hazards of extended pioglitazone-based treatments. Given the drug’s detriments as well as benefits, clear and effective labeling is important. Sadly, however, insufficient product information has left some patients making decisions that aren’t necessarily in their best interest.
Ready to talk to the dedicated attorneys and professionals at Fears Nachawati about whether Actos’s insufficient labeling may have violated your rights? We know how to give you the advice and perspective you need. For your free consultation, call us at 1.866.545.8364 or email mn@fnlawfirm.com. We’re ready to fight for you!